IL17A and neoplasm: First, although numerous studies support the potential value of blocking IL-17A for antitumor therapy, some researchers are cautious about the dual role of Th17/IL-17A signaling in tumor progression.48 We believe that it is based on the specific immune landscape, and the application of anti-IL-17A therapy under appropriate conditions could achieve a significant therapeutic effect, including in combination with ICIs therapy.